Pragmatic precision oncology: The secondary uses of clinical tumor molecular profiling

Journal of the American Medical Informatics Association

Volumn 23, Issue 4, 2016, Pages 773-776

  Rioth, Matthew J ^a,b   Thota, Ramya ^a   Staggs, David B ^b   Johnson, Douglas B ^a   Warner, Jeremy L ^a,b  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ACCURACY; ALGORITHM; ARTICLE; ASSAY; CANCER LOCALIZATION; CLINICAL TRIAL (TOPIC); DATA BASE; DISEASE CLASSIFICATION; GENETIC SCREENING; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; ONCOLOGY; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; SARCOMA; SCIENTIFIC LITERATURE; TUMOR GENE; VALIDATION STUDY; GENE EXPRESSION PROFILING; GENETIC DATABASE; GENETICS; NEOPLASM;

DATABASES, GENETIC; GENE EXPRESSION PROFILING; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PRECISION MEDICINE;

EID: 84981287117     PISSN: 10675027     EISSN: 1527974X     Source Type: Journal    
DOI: 10.1093/jamia/ocw002     Document Type: Article

References (25)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
2. Chairperson TJH, Anderson W, Aretz A, et al. International network of cancer genome projects. Nature. 2010;464:993-998.
3. Santarpia L, Qi Y, Stemke-Hale K, et al. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat. 2012;134:333-343.
4. Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov. 2013;3:27-34.
5. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883-892.
6. Van Allen EM, Wagle N, Levy MA. Clinical analysis and interpretation of cancer genome data. J Clin Oncol. 2013;31:1825-1833.
7. Tsimberidou AM, Eggermont AMM, Schilsky RL. Precision cancer medicine: the future is now, only better. Am Soc Clin Oncol Educ Book ASCO Am Soc Clin Oncol Meet. 2014;61-69.
8. Dancey JE, Bedard PL, Onetto N, et al. The genetic basis for cancer treatment decisions. Cell. 2012;148:409-420.
9. Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023-1031.
10. Clinical Genomics. http://www.hl7.org/Special/committees/clingenomics/. Accessed November 15, 2015.
11. Rioth M, Staggs D, Warner J. Incorporation of externally generated nextgeneration tumor genotyping into clinical and research workflows: Successes and lessons learned. J Clin Oncol. 2014;32:abstr 156.
12. Rioth MJ, Staggs D, Hackett L, et al. Implementing and improving automated electronic tumor molecular profiling. J Oncol Pr. 2016;12:e332-e337.
13. Danciu I, Cowan JD, Basford M, et al. Secondary use of clinical data: the Vanderbilt approach. J Biomed Inf. 2014;52:28-35.
14. Human Genome Variation Society. http://www.hgvs.org/. Accessed November 15, 2015.
15. Dunnen JT den, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat. 2000;15:7-12.
16. Johnson DB, Dahlman KH, Knol J, et al. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist. 2014;19:616-622.
17. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377-381.
18. Clovis Oncology. A Study to Assess the Safety and Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGF Aberrant Metastatic Breast Cancer. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine 2015.
19. Conley BA, Doroshow JH. Molecular analysis for therapy choice: NCI MATCH. Semin Oncol. 2014;41:297-299.
20. NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) Trial. Natl. Cancer Inst. http://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/ nci-match. Accessed August 22, 2015.
21. Ledford H. 'Master protocol' aims to revamp cancer trials. Nature. 2013;498:146-147.
22. Sleijfer S, Bogaerts J, Siu LL. Designing transformative clinical trials in the cancer genome era. J Clin Oncol. 2013;31:1834-1841.
23. Bowton E, Field JR, Wang S, et al. Biobanks and electronic medical records: enabling cost-effective research. Sci Transl Med. 2014;6:234cm3-234cm3.
24. Gottesman O, Kuivaniemi H, Tromp G, et al. The electronic medical records and genomics (eMERGE) network: past, present, and future. Genet Med. 2013;15:761-771.
25. Alterovitz G, Warner J, Zhang P, et al. SMART on FHIR Genomics: facilitating standardized clinico-genomic apps. JAMIA. Published Online First: July 21 2015;22:1173-1178.